FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
FSTX Financial Statements
Year
2021
2020
2019
2018
CF from Operating Activities
-27.27M
-16.23M
-22.11M
-25.24M
Net Income
-31.28M
-25.62M
-23.01M
-22.85M
Depreciation & Amortization
642k
1.14M
844k
288k
Deferred Income Taxes
-104k
345k
4.25M
-180k
Stock Based Compensation
6.9M
3.49M
2.67M
2.78M
Change in Working Capital
-4.92M
1.03M
-8.51M
180k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
-1.5M
-2.85M
2.26M
180k
Other Working Capital
-3.42M
3.87M
-10.77M
-180k
Other Non-Cash Items
1.5M
3.39M
1.65M
-5.45M
CF from Investing Activities
-643k
14.05M
5.37M
-25.1M
Investments in Property, Plant & Equipment
-658k
-730k
-127k
-1.97M
Net Acquisitions
0
0
5.5M
0
Investment Purchases
0
0
-15M
-58M
Sales/Maturities of Investments
0
5M
38.77M
34.87M
Other Investing Activites
15k
9.78M
-23.77M
0
CF from Financing Activities
88.1M
15.85M
13.26M
41.17M
Debt Repayment
0
0
0
0
Common Stock Issued
78.35M
15M
6k
37.96M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
88.1M
15.85M
13.26M
41.17M
Free Cash Flow
-27.93M
-16.96M
-22.24M
-27.22M
Operating Cash Flow
-27.27M
-16.23M
-22.11M
-25.24M
Capital Expenditures
-658k
-730k
-127k
-1.97M
Cash at Beginning of Period
18.53M
4.9M
8.2M
24.13M
Cash at End of Period
78.55M
18.53M
4.9M
14.96M
Net Change In Cash
60.02M
13.63M
-3.29M
-9.18M
Retained Earning Schedule
Year
2021
2020
2019
2018
Retained Earnings (Previous Year)
-47.17M
-21.55M
-102.07M
-79.21M
Net Income
-31.28M
-25.62M
-23.01M
-22.85M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-78.45M
-47.17M
-21.55M
-102.07M
Other Distributions
-31.28M
-25.62M
80.52M
-22.85M
PPE Schedule
Year
2021
2020
2019
2018
Gross PPE
4.17M
3.57M
2.03M
2.32M
Annual Depreciation
1.29M
1.14M
9.15M
288k
Capital Expenditure
-658k
-730k
-127k
-1.97M
Net PPE
3.53M
3.16M
-6.99M
4M
Intangible and Goodwill Schedule
Year
2021
2020
2019
2018
Acquisitions and Adjustments
-28k
10.61M
4.32M
0
Goodwill (Previous Year)
14.93M
4.32M
0
0
Goodwill
14.9M
14.93M
4.32M
0
All figures are in USD.
